C4 Therapeutics (CCCC) Change in Acquisitions & Divestments (2019 - 2026)

C4 Therapeutics has reported Change in Acquisitions & Divestments for 7 years, with the latest figure at $57.0 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Acquisitions & Divestments rose 4.13% year-over-year to $57.0 million; the trailing twelve-month figure through Mar 2026 stood at $221.3 million (down 5.26% YoY), and the FY2025 full-year result was $219.1 million, down 6.07% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $57.0 million, up from $52.3 million in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $90.3 million in Q3 2023, with the low at $51.2 million in Q3 2025.
• Average Change in Acquisitions & Divestments over 5 years is $63.7 million, with a median of $64.2 million recorded in 2023.
• Peak annual rise in Change in Acquisitions & Divestments reached 44.85% in 2022, while the deepest fall reached 37.05% in 2022.
• Tracing CCCC's Change in Acquisitions & Divestments over 5 years: stood at $67.1 million in 2022, then grew by 4.35% to $70.0 million in 2023, then decreased by 22.19% to $54.4 million in 2024, then declined by 3.86% to $52.3 million in 2025, then rose by 8.94% to $57.0 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $57.0 million (Q1 2026), $52.3 million (Q4 2025), and $51.2 million (Q3 2025), per Business Quant data.

Peer Comparison